Companies / TLX

TELIX PHARMACEUTICALS LIMITED

ASX:TLXPharmaceuticals, Biotechnology & Life Sciences
339.8M shares on issueASX (delayed) · as of 28 July 2026$14.28price · delayed$4.98Bmarket cap · indicative
B
Dilution grade

4 cash raises in 24 months

Cash runwayno data — no longer lodges quarterly cash reports (4C/5B)
Share-count growth (24m)1.5%
Raise cadence (24m)4 cash raises
Options & rights overhangno data — options line data suspect
In-the-money supplyno data — options line data suspect
Pending proposed issuesnone

TELIX PHARMACEUTICALS LIMITED's ordinary share count was 340M as of July 2026, up 1.5% since July 2024. The company completed four capital raises in the 24-month window for total disclosed proceeds of A$1.2B, most recently issuing convertible notes that raised A$600.0M in April 2026. Options overhang data is omitted because the outstanding option-line data on record is treated as suspect for this company. The company no longer lodges quarterly cash reports, so no quarterly cash balance or funding-runway figure applies. There are no proposed securities issues (Appendix 3B) currently pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
—
Max option dilution · omitted
—
ITM option dilution
2
Raises · last 12 months
—
Cash cover · stale filings

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 339.8M per ASX (delayed) (28 July 2026).
335.8M337.3M338.7MDec 24Sept 25July 26Cash raise · 15 Apr 2026Cash raise · 13 Apr 2026Cash raise · 3 Apr 2025Cash raise · 21 Mar 2025

Cash runway

—
stale Last quarterly cash report is more than 12 months old (quarter ended 30 Sept 2023) — runway is not computed from stale filings.
$139.5M available cash reported at 30 Sept 2023.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 Sept 2023.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
9 July 20262A · quoted issueTLX : ORDINARY FULLY PAID339.8MAppendix 2A
9 July 20263H · cancellationTLX : ORDINARY FULLY PAID339.4MAppendix 3H
9 July 20263G · unquotedORDINARY FULLY PAID339.4MAppendix 3G
1 June 20263G · unquotedORDINARY FULLY PAID339.4MAppendix 3G
7 May 20262A · quoted issueTLX : ORDINARY FULLY PAID339.4MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

4 cash raises in the last 24 months · 2 in the last 12 months

$600.0M
Convertible Notes
15 Apr 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

Options summary omitted. options line data suspect

Director dealings

DateDirectorTypeSharesOptionsValueSource
11 June 2026David GillBuy10k——3Y notice
26 May 2026Maria RivasOther—22k—3Y notice
26 May 2026Marie McDonaldOther4k23k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026Change in substantial holding
20 July 2026$PQ2 2026 Revenue US$247M Strong Momentum Pipeline Progress
9 July 2026Notification of cessation of securities - TLX
9 July 2026Notification regarding unquoted securities - TLX
9 July 2026Application for quotation of securities - TLX
8 July 2026Change in substantial holding
3 July 2026Ceasing to be a substantial holder
2 July 2026$PFDA Alignment to Advance ProstACT Global Phase 3 Trial
1 July 2026Change in substantial holding
30 June 2026Change in substantial holding
30 June 2026Becoming a substantial holder
24 June 2026Becoming a substantial holder
23 June 2026Ceasing to be a substantial holder
16 June 2026Appendix 3Y Change in Director Interest D Gill
8 June 2026Change in substantial holding
1 June 2026Notification regarding unquoted securities - TLX
1 June 2026Appendix 3Y Change in Director Interest - C Behrenbruch
1 June 2026Appendix 3Y Change in Director Interest - M McDonald
1 June 2026Appendix 3Y Change in Director Interest - W Jellison
1 June 2026Appendix 3Y Change in Director Interest - Maria Rivas

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.